Search

DelveInsight reported its 'Schizophrenia Pipeline Insight 2024' report provides comprehensive global coverage of pipeline schizophrenia in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline [...]

2024 AUG 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained […]

Yingshuo Biotechnology announced that Paliperidone ER Tablet has obtained the Malaysian drug license, becoming Yingshuo's first drug in Malaysia. Partner Company H will be responsible for local sales, which is [...]

2023 NOV 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on pharmaceutics are presented in a new report. According to [...]

I recently came upon a Substack essay by Aruna K Tummala, MD, that examined the hazards of relying solely on psychiatric medications, which are standard-of-care, to treat mental illnesses. [1] [...]

A study conducted at York University in Toronto, Canada, explored the demographic, mental health, and substance use factors associated with the use of hallucinogens for medicinal purposes. The research found that individuals who reported using hallucinogens for medicinal reasons had greater depression severity, more frequent use of alcohol, cannabis, and nicotine, and used several illegal and prescription drugs. They also reported using hallucinogens more frequently compared to those who used them exclusively for recreational purposes. These findings may help inform targeted interventions for the use of hallucinogens. The study was published in the International Journal of Mental Health and Addiction. [Extracted from the article]

A recent study conducted by the Copenhagen Affective Disorder Research Center (CADIC) in Denmark found that the majority of individuals in the country have either received a diagnosis of a mental health disorder or have been prescribed psychotropic medication during their lifetime. The study, which analyzed data from a representative sample of 1.5 million individuals, also revealed that these mental health conditions were associated with subsequent socioeconomic difficulties, such as lower income, unemployment, and living alone. The researchers hope that these findings will contribute to a better understanding of mental illness, reduce stigma, and prompt the development of prevention strategies and mental health resources. [Extracted from the article]

A study conducted by researchers at George Washington University examined the relationship between hallucinogen use and mental health outcomes in a nationally representative sample. The study found that psychedelic use was associated with reduced odds of psychological distress in heterosexual individuals, but this relationship was not significant in sexual minority groups. The researchers suggest that future research should investigate why hallucinogen use was not protective in sexual minority groups, who often experience poor mental health outcomes. The study highlights the potential benefits of psychedelic-assisted therapy for mental health, but also underscores the need for further investigation into its effects on diverse populations. [Extracted from the article]

A recent study conducted by researchers from the Manitoba Center for Health Policy examined the patterns of concurrent opioid and psychotropic drug use during pregnancy in two Canadian provinces. The study found that approximately 1.4% of pregnancies involved the concurrent use of these drugs. Mothers who were dispensed multiple opioids were more likely to engage in concurrent drug use, and the strength of opioids used by these mothers was higher compared to those who only used opioids. The study suggests that further research is needed to understand the impact of concurrent drug use on maternal and child outcomes. [Extracted from the article]

There is a mental health crisis in the United States. With too few providers available for the number of individuals seeking counseling and treatment, pharmacists may be able to step [...]

Sen. Charles Grassley (R-IA) is demanding to know why federal regulators find it a “burden” to audit nursing homes with a high rate of prescribing psychotropic drugs to residents. The [...]

2023 FEB 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on drug development have been published. According to news [...]

A systematic review conducted by the University of Southern Denmark examined the use of psychotropic drugs among children and adolescents in the Nordic countries. The review found significant variations in psychotropic drug use among different Nordic countries, despite their similar populations and healthcare systems. The use of psychotropic drugs, such as antidepressants and psychostimulants, varied greatly between countries. The study suggests that further investigation is needed to address these national variations and improve rational pharmacotherapy for youths with psychiatric disorders. [Extracted from the article]

A recent study conducted by researchers at Umea University in Sweden examined the long-term effects of parental job loss on child mental health. The study utilized intergenerationally linked Swedish register data to track 400,000 children over 14 years. The results showed that paternal job loss, but not maternal job loss, significantly increased the risk of psychotropic drug use among children. The effects were modest in size, lasting up to five years, and were most pronounced in children aged 6-10 years. Additionally, cumulative exposure to multiple job losses was found to be more harmful than experiencing no or only one job loss. The study was supported by the European Research Council and has been peer-reviewed. [Extracted from the article]

* Investigators studied a U.S. commercial insurance database to evaluate trends in the use of prescribed stimulants, including co-prescribing with other psychotropic drugs. * A total of 3% of those in the database filled at least one prescription claim for a schedule II stimulant in 2020, and the median duration of exposure to stimulants was 227 days. * Among those using stimulants, 45.5% were concomitantly exposed to at least one other central nervous system-active drug., Nearly half of a group of commercially insured U.S. patients using a prescription stimulant in 2020 were also receiving a prescription for another drug acting on the central nervous system [...]

Back in November 2020, a point in our history that you may recall as marked by, one could say, 'disquiet,' I wrote a commentary addressing an issue of pharmacoeconomics pertaining [...]

Byline: Laxmi Yadav Close on the heels of a crackdown on online pharmacy Netmeds for selling narcotics and psychotropic drugs in violation of Drugs and Cosmetics Act and Rules thereunder, [...]

Yingshuo Biotechnology (hereinafter referred to as 'Yingshuo', stock code: 6677), a professional drug delivery technology developer, said today (27) that in order to accelerate the commercialization of its nanocrystalline injection [...]

2022 SEP 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Nanotechnology - Nanocomposites have been presented. According to news [...]

Byline: Laxmi Yadav In a bid to curb abuse of narcotic drugs and psychotropic substances as intoxicants in the state, the Food Safety and Drug Administration (FSDA) Department, Uttar Pradesh [...]

2022 AUG 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Antipsychotics have been published. [...]

Byline: Peethaambaran Kunnathoor The drugs control department in Tamil Nadu is gearing up to launch a massive crackdown on medical shops in Thiruvannamalai and Kumbhakonam this week following reports of [...]

In this month’s case, a state appeals court was asked to review the decision of an Administrative Law Judge allowing a state hospital to administer psychotropic medications to a patient [...]

A recent report from researchers at the University of Hong Kong-Shenzhen Hospital explores the potential of N, N-dimethyltryptamine (DMT), a natural hallucinogen, in treating Alzheimer's disease (AD). The study suggests that DMT may have anti-AD effects by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk. In experiments with transgenic mice, chronic DMT administration improved cognitive impairment, reduced amyloid-beta accumulation, and restored Sig-1r levels. The findings indicate that DMT has the potential to be a novel preventive and therapeutic agent for AD. [Extracted from the article]

A report from the University of Toronto discusses the issue of psychotropic drug-related weight gain (PDWG) and its impact on psychiatric patients. The research highlights that PDWG is a common occurrence and is associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs. The study suggests that certain classes of drugs have lower or no liability for PDWG and should be prioritized. Additionally, lifestyle and behavioral modifications, as well as pharmacological treatments like metformin and GLP-1 receptor agonists, show promise in preventing and treating PDWG. The research calls for further studies to explore the effectiveness of these treatments and specific dietary modifications. [Extracted from the article]

A study conducted at the Pontificia Universidade Catolica do Rio Grande do Sul in Brazil examined the process of deprescribing psychotropic drugs in older patients at a geriatric psychiatry outpatient clinic. The study collected data from 150 older patients and found that deprescription of at least one psychotropic drug was indicated in 61.3% of participants, with 68.5% of those cases effectively implemented. The main classes of drugs indicated for deprescription were hypnotics and sedatives, as well as anxiolytics. The research concluded that deprescription was successful in more than half of the prescribed psychotropic drugs. [Extracted from the article]

A recent study conducted by McMaster University in Hamilton, Canada examined the relationship between QTc interval prolongation (a risk factor for sudden cardiac death) and extrinsic factors such as electrolyte abnormalities and the use of psychotropic drugs in pediatric patients with eating disorders (EDs). The study found that EDs alone may not prolong QTc intervals, but the use of psychotropic drugs appears to be a significant external factor in QTc prolongation. The research suggests that further investigation is needed to better understand the impact of psychotropic drugs on QTc intervals in pediatric patients with EDs. [Extracted from the article]

A recent report from Osaka University in Japan discusses the findings of a study on schizophrenia. The researchers focused on the role of the KPNA1 gene in schizophrenia pathogenesis. They found that mice with a deficiency in KPNA1 exhibited behavioral abnormalities consistent with schizophrenia symptoms when administered a psychotropic drug. The study suggests that these mice could serve as a useful model for studying gene-environment interactions in psychiatric disorders. Further research is needed to better understand the underlying mechanisms of schizophrenia. [Extracted from the article]

Byline: A Raju, Hyderabad The Narcotics Control Bureau (NCB) has nailed an online pharmacy store run by a private company which was involved in supplying psychotropic medicine to foreign countries [...]

Byline: A Raju The Narcotics Control Bureau (NCB) has nailed an online pharmacy store run by a private company which was involved in supplying psychotropic medicine to foreign countries like [...]

2022 MAR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on toxicology. According to news reporting originating from [...]

UNTIL THE SPRING of 2018, Jonathan Kaiman was the Beijing bureau chief of the Los Angeles Times. Today he is living at the home of his parents in Phoenix under [...]

Researchers at the Beijing Institute of Pharmacology and Toxicology have conducted a study on the effects of antipsychotic drugs on hallucinogenic behavior induced by a specific hallucinogen called 2,5-dimethoxy-4-methylamphetamine (DOM). The study evaluated the therapeutic potential of three 5-HT2A receptor antagonists: ketanserin, M100907, and olanzapine. The researchers found that these drugs had varying efficacy in reducing hallucination-like behavior in mice. This study provides experimental evidence for potential therapeutic drugs against hallucinogenic behavior induced by DOM. [Extracted from the article]

A recent study conducted in Denmark found that patients with eosinophilic oesophagitis (EoE) have a higher use of psychotropic drugs (PDs) compared to the general population. EoE is a chronic, immune-mediated disease of the esophagus that can have a significant impact on quality of life and mental health. The study, which included 3367 EoE patients and 16,835 age- and sex-matched comparators, found that the 5-year incidence of PD use in EoE patients was 13.8% compared to 7.1% in the general population. Antidepressants were the most commonly prescribed PDs for EoE patients. The study suggests that EoE patients may have an increased risk of psychiatric disorders. [Extracted from the article]

A study conducted at Lille University Hospital in France explored the use of therapeutic drug monitoring and pharmacogenetic testing to personalize treatments with psychotropic drugs. The study included 490 inpatients, mainly monitoring clozapine and quetiapine, and found that 51% of patients had drug concentrations within the therapeutic range. However, drug management did not change in 83% of cases, regardless of drug concentration. The study concluded that knowledge of a patient's drug concentration and metabolic status can help optimize psychotropic drug adjustment, with support from a multidisciplinary team and decision support tools. [Extracted from the article]

A study conducted by the University of Southern California School of Pharmacy examined the documentation of psychotropic drug-drug interactions (DDIs) in an adult psychiatric clinic. The researchers found that many DDIs go undetected or unmanaged, highlighting the importance of thorough documentation to improve patient safety. The study reviewed charts of patients prescribed high-alert psychotropic medications and identified 146 DDIs among 129 patients. The documentation of these interactions was found to be lacking, with 65% of DDIs not documented at all. The researchers propose best practices for DDI documentation, including description and potential outcome of the interaction, monitoring and management, patient education, and patient response to education. Strategies to improve documentation quality include targeted provider education, incentives, and the use of electronic medical record 'DDI smart phrases.' [Extracted from the article]

2021 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Drugs and Therapies - Pharmacology. According to [...]

A brief staff training session on good drug practices for older adults led to significant reduction in psychotropic drug use in assisted living communities, a new study from Finland finds. [...]

Byline: Peethaambaran Kunnathoor The Tamil Nadu Drugs Control Department is gearing up to launch prosecution against 77 drug retailers belonging to all districts in the state for violation of conditions [...]

A study conducted by researchers from Umea University in Sweden examined the use of psychotropic drugs among older individuals with major neurocognitive disorder (NCD) and compared it to a reference group. The study found that psychotropic drug use was higher among individuals with major NCD, particularly those residing in nursing homes. The research highlighted the need for interventions to better address neuropsychiatric symptoms in older individuals, with a focus on reducing hypnotic drug use and antipsychotic drug exposure in nursing homes. The study was published in the International Journal of Geriatric Psychiatry. [Extracted from the article]

A recent study conducted by researchers at Harvard University examined the associations between individual hallucinogens and hallucinogen misuse among adults in the United States who recently initiated hallucinogen use. The study used data from the National Survey on Drug Use and Health from 2015 to 2020 and employed multivariable logistic regression to analyze the relationships between lifetime use of seven specific hallucinogens and hallucinogen dependence and abuse. The findings revealed that lifetime use of PCP was associated with increased odds of hallucinogen dependence and abuse, while LSD, ketamine, and mescaline were also found to confer increased odds of certain criteria. The researchers suggest that future longitudinal studies and Bayesian statistical analyses can further explore the relationships between hallucinogens and disordered hallucinogen use. [Extracted from the article]

Located in downtown Las Vegas, the Clark County Detention Center is the largest jail in the state of Nevada, with an average daily population of more than 4,200 inmates and [...]

The Supreme Court Committee on Standard Jury Instructions in Criminal Cases submits the following new and amended instructions to the Florida Standard Jury Instructions in Criminal Cases for comment. The [...]

Keywords: Pharmaceuticals; Zurich; Europe; Cancer; Hormones; Oncology; Switzerland; Psychiatric; Mental Health; Glucocorticoids; Mental Disorders; Prednisone Therapy; Psychotropic Drugs; Drugs and Therapies; Health and Medicine; Adrenal Cortical Steroids; Central Nervous System Agents EN Pharmaceuticals Zurich Europe Cancer Hormones Oncology Switzerland Psychiatric Mental Health Glucocorticoids Mental Disorders Prednisone Therapy Psychotropic Drugs Drugs and Therapies Health and Medicine Adrenal Cortical Steroids Central Nervous System Agents New research on Mental Disorders is the subject of a report. Pharmaceuticals, Zurich, Europe, Cancer, Hormones, Oncology, Psychiatric, Switzerland, Mental Health, Glucocorticoids, Prednisone Therapy, Psychotropic Drugs, Drugs and Therapies, Health and Medicine, Adrenal Cortical Steroids, Central Nervous System Agents, Mental Disorders. [Extracted from the article]

Concurrent psychotropic drug use is quite common in the VA population with epilepsy, and a large number of patients still receive enzyme-inducing ASMs that may complicate other medical therapies. Keywords: Madison; State:Wisconsin; United States; North and Central America; Brain Diseases and Conditions; Central Nervous System Agents; Central Nervous System Diseases and Conditions; Drugs and Therapies; Epilepsy; Health and Medicine; Mental Health; Military and Defense; Psychiatric; Psychiatry; Psychotropic Drugs; Veterans EN Madison State:Wisconsin United States North and Central America Brain Diseases and Conditions Central Nervous System Agents Central Nervous System Diseases and Conditions Drugs and Therapies Epilepsy Health and Medicine Mental Health Military and Defense Psychiatric Psychiatry Psychotropic Drugs Veterans 1706 1706 1 09/04/23 20230908 NES 230908 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- New research on Veterans is the subject of a report. [Extracted from the article]